StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a note issued to investors on Monday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Up 0.8 %

NURO stock opened at $4.42 on Monday. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $4.73. The company has a market cap of $9.05 million, a P/E ratio of -0.96 and a beta of 2.18. The business’s fifty day moving average is $4.14 and its 200-day moving average is $4.02.

Institutional Trading of NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC bought a new position in NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned 1.12% of NeuroMetrix as of its most recent filing with the Securities & Exchange Commission. 19.40% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.